A study showed that the use of engineered T cells with CARs, and scFv from antibodies targeting VEGFR2, showed durable and increased T cells entry into tumors, a phenomenon correlating with the suppression of tumor progression [109]. This evidence concerns the gene KDR and neoplasm.